$1.33
3.62% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US58468P2065
Symbol
MNOV
Sector
Industry

MediciNova, Inc. Stock price

$1.33
-0.13 8.90% 1M
-0.77 36.67% 6M
-0.77 36.67% YTD
-0.04 2.92% 1Y
-5.03 79.09% 5Y
-2.71 67.08% 10Y
-9.62 87.85% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.05 3.62%
ISIN
US58468P2065
Symbol
MNOV
Sector
Industry

Key metrics

Market capitalization $67.68m
Enterprise Value $31.11m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.36
Free Cash Flow (TTM) Free Cash Flow $-10.56m
Cash position $36.57m
P/E forward negative
Short interest 0.40%

Is MediciNova, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

MediciNova, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MediciNova, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MediciNova, Inc.:

Buy
100%

Financial data from MediciNova, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.13 4.13
21% 21%
-
- Research and Development Expense 5.41 5.41
4% 4%
-
-9.52 -9.52
4% 4%
-
- Depreciation and Amortization 0.02 0.02
0% 0%
-
EBIT (Operating Income) EBIT -9.54 -9.54
4% 4%
-
Net Profit -8.30 -8.30
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about MediciNova, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediciNova, Inc. Stock News

Neutral
GlobeNewsWire
2 months ago
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital's, Inaugural DBC Confer...
Neutral
GlobeNewsWire
2 months ago
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclero...

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Head office United States
CEO Yuichi Iwaki
Employees 13
Founded 2000
Website medicinova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today